BMO Capital Reiterates Outperform Rating on Merus N.V. (MRUS)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/21/2026
Go back to BMO Capital Reiterates Outperform Rating on Merus N.V. (MRUS)
May 23, 2024 5:00 PM EDT
MCLA-145 monotherapy and in combination with pembrolizumab rapid oral session presentation: June 2, 2024, 11:30 a.m.-1:00 p.m. CT
MCLA-129 in NSCLC with c-MET exon 14 skipping mutations poster presentation: June 3, 2024, 1:30-4:30 p.m. CT
UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 23, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a... More
May 23, 2024 5:00 PM EDT
-Â Â 60% response rate observed among 10 evaluable patients
-Â Â Favorable safety profile in 26 patients enrolled as of the abstract cutoff date, with no significant overlapping toxicities observed
-  Conference call on Tuesday, May 28 at 8:00 a.m. ET to discuss full ASCO® data set
UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 23, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:... More
